| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
MDP1 acetate targets the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor, an intracellular pattern recognition receptor that detects bacterial muramyl dipeptide (MDP) and activates NF-kappaB signaling to promote pro-inflammatory cytokine production.
|
|---|---|
| ln Vitro |
MDP1 acetate demonstrates enhanced antibacterial efficacy against S. aureus, E. coli, and P. aeruginosa. The geometric means of MICs for MDP1 are 4.06 μg/mL for S. aureus, 1.22 μg/mL for E. coli, and 3.75 μg/mL for P. aeruginosa, in that order[1]. Assays using DNA, calcein release, and flow cytometry demonstrate a time-dependent antibacterial activity against the tested bacteria that are impacted by MDP1(10, 5, 2.5, 1.25, 0.625, and 0.312 μg/mL) acetate. Ultimately, SEM analyses demonstrate how MDP1 acetate affects S. aureus and E. coli bacteria in a dose- and time-dependent manner by causing vesicle or pore development and cell lysis[1].
Not available. MDP1 acetate activates NOD2 signaling to induce NF-kappaB translocation and upregulation of pro-inflammatory gene expression. In THP-1 human monocytic cells, MDP synergizes with TLR agonists to markedly induce IL-8 secretion in a NOD2-dependent manner. |
| ln Vivo |
Not available. In mouse models, intravenous injection of NOD2 agonists including MDP1 acetate exhibits analgesic activity at doses of 10 ug/head in BALB/c mice. NOD2 activation can also modulate metabolic parameters including insulin resistance and hepatic glucose output.
|
| Enzyme Assay |
Not available. For NOD2 binding assays, typical protocols involve incubation of MDP1 with NOD2 protein in cell lysates, followed by pull-down using affinity tags and detection by Western blotting or ELISA to assess binding affinity.
|
| Cell Assay |
Not available. For NOD2 activation assays, standard protocols involve treating THP-1 cells or primary monocytes with MDP1 acetate at concentrations ranging from 1-100 microg/mL for 4-24 hours, followed by measurement of IL-8, TNF-alpha, or IL-1beta by ELISA.
|
| Animal Protocol |
Not available. For in vivo NOD2 studies, typical protocols involve intraperitoneal or intravenous administration of MDP1 acetate (0.1-10 mg/kg) in mice, followed by assessment of cytokine levels in serum, analysis of inflammatory markers, or pain response measurement.
|
| ADME/Pharmacokinetics |
Not available. As a synthetic lipopeptide, pharmacokinetic properties may include rapid clearance and distribution to immune compartments; lipidation enhances membrane permeability and potentially extends circulation time compared to unmodified peptides.
|
| Toxicity/Toxicokinetics |
Not available. NOD2 agonists generally exhibit acceptable tolerability at immunomodulatory doses in animal studies; however, excessive NOD2 activation can contribute to inflammatory pathology. Specific toxicological data for MDP1 acetate are not reported.
|
| References |
[1]. Akbari R, et al. Action mechanism of melittin-derived antimicrobial peptides, MDP1 and MDP2, de novo designed against multidrug resistant bacteria. Amino Acids. 2018;50(9):1231-1243.
|
| Additional Infomation |
MDP1 acetate is a research-grade immune modulator used to study innate immunity, NOD2 signaling, inflammation, and host-pathogen interactions. It has not progressed to clinical trials nor received regulatory approval for therapeutic indications. Its mechanism involves NF-kappaB activation and pro-inflammatory cytokine production, making it a valuable tool for immunology research.
|
| Molecular Formula |
C113H206N34O30
|
|---|---|
| Related CAS # |
MDP1
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~10 mg/mL (~3.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (19.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
